Bank of Hawaii’s Cogent Biosciences COGT Stock Holding History

Bank of Hawaii’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-26,142	Closed	-$929K	–	228
2025 Q4	$929K	Buy	+26,142	New	+$735K	0.05%	142

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Bank of Hawaii's COGT Position: Q1 2026 in Review

Bank of Hawaii sold out of Cogent Biosciences (COGT) in Q1 2026, closing a stake of 26,142 shares — an estimated $929K sold.

Bank of Hawaii first reported a position in COGT in Q4 2025 and held it in 1 quarter. The position peaked at $929K in Q4 2025. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

Bank of Hawaii reported no remaining Cogent Biosciences position as of Q1 2026 after selling out during the quarter.
Bank of Hawaii sold 26,142 Cogent Biosciences shares in Q1 2026, an estimated $929K.
Bank of Hawaii first reported a position in Cogent Biosciences in Q4 2025 and held it in 1 quarter.
Bank of Hawaii's Cogent Biosciences position peaked at $929K in Q4 2025.
305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Bank of Hawaii's 13F filing for Q1 2026, filed 15 May 2026.